Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Drug Monitoring of Asparaginase Activity to Detect Silent Inactivation in Pediatric Acute Lymphoblastic Leukemia Patients Receiving Peg-Asparaginase

Van Thu Huynh, MD, Alexa Love, BA, Mary English, CPNP, Carol Hwang Lin, MD

Blood (2018) 132 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2018-99-117165

Published: 2018

Journal Articles

Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns

Muhammad Effendi, PharmD, Martha Stutsky, PharmD, Caleigh A. Curran, PharmD, Kent A. Owusu, PharmD, Alfred Ian Lee, MD PhD

Blood (2018) 132 (Supplement 1): 2284.

https://doi.org/10.1182/blood-2018-99-119379

Published: 2018

Journal Articles

Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Eytan M. Stein, MD, Jipan Xie, MD PhD, Emilie Duchesneau, Subrata Bhattacharyya, PhD, Briana Ndife, MPH, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD

Blood (2017) 130 (Supplement 1): 4703.

https://doi.org/10.1182/blood.V130.Suppl_1.4703.4703

Published: 2017

Journal Articles

Evaluating Frequency of Anti-Xa Monitoring in Treatment of Pediatric Venous Thromboembolism

Laura E Roberts, MD, Jennifer L Fan, MSIV, YoungNa J Lee-Kim, MD, Mona D Shah, MD MS

Blood (2015) 126 (23): 2333.

https://doi.org/10.1182/blood.V126.23.2333.2333

Published: 2015

Journal Articles

Efficacy and Safety of Rivaroxaban: An Observationalmulticenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT

Manuela Krause, MD, Alexander Bauer, Hartmut Clausnizer, Gili Kenet, MD, Dorothee Kowalski, Verena Limperger, Ann-Kathrin Pilgrimm-Thorp, Daniela Manner, MD, Ulrike Nowak-Göttl, Prof.

Blood (2014) 124 (21): 5083.

https://doi.org/10.1182/blood.V124.21.5083.5083

Published: 2014

Journal Articles

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

Wing H. Tong, Rob Pieters, Gertjan J. L. Kaspers, D. Maroeska W. M. te Loo, Marc B. Bierings, Cor van den Bos, Wouter J. W. Kollen, Wim C. J. Hop, Claudia Lanvers-Kaminsky, Mary V. Relling, Wim J. E. Tissing, Inge M. van der Sluis

Blood (2014) 123 (13): 2026–2033.

https://doi.org/10.1182/blood-2013-10-534347

Published: 2014

Includes: Supplemental data

Journal Articles

Intensified Mycophenolate Mofetil (MMF) Dosing Every 8 Hours Is Safe From The Standpoint Of Engraftment and May Ameliorate Severe Acute Graft-Versus-Host Disease (GVHD) After Double-Unit Cord Blood Transplantation (CBT)

Doris M Ponce, MD, Stephen J. Harnicar, PharmD, BCOP, BCPS, Sean Devlin, PhD, Patrick Hilden, MS, Katherine L Evans, BA, Marissa N Lubin, BA, Sergio A Giralt, MD, Jenna D Goldberg, MD, Miguel-Angel Perales, MD, Nancy A. Kernan, MD, Susan E. Prockop, MD, Andromachi Scaradavou, MD, Juliet N Barker, MBBS, (Hons), FRACP

Blood (2013) 122 (21): 4600.

https://doi.org/10.1182/blood.V122.21.4600.4600

Published: 2013

Journal Articles

Should We Use a Desensitization Protocol In Acute Lymphoblastic Leukemia Patients With Silent Inactivation Of Pegasparaginase?

Wing H. Tong, MD, Rob Pieters, Wim J Tissing, MD, PhD, Inge M. van der Sluis, MD, PhD

Blood (2013) 122 (21): 1434.

https://doi.org/10.1182/blood.V122.21.1434.1434

Published: 2013

Journal Articles

A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia

Wing H. Tong, MD, Rob Pieters, Gertjan Kaspers, MD, PhD, Maroeska D.W.M. te Loo, MD, PhD, Marc Bierings, Cor van den Bos, MD, PhD, Wouter J.W. Kollen, MD, PhD, Wim C.J. Hop, PhD, Joachim Boos, MD, PhD, Mary V. Relling, PharmD, Hans Juergen Kuehnel, MD, Wim J Tissing, MD, PhD, Inge M. van der Sluis, MD, PhD

Blood (2013) 122 (21): 2634.

https://doi.org/10.1182/blood.V122.21.2634.2634

Published: 2013

Journal Articles

Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients

Stephen J. Harnicar, PharmD, BCOP, BCPS, Doris M Ponce, MD, David Gregornik, PharmD, Sherry Mathew, PharmD, BCOP, Katherine L Evans, BA, Junting Zheng, MS, Sean Devlin, PhD, Melissa Pozotrigo, PharmD, BCOP, Andromachi Scaradavou, MD, Nancy A. Kernan, MD, Nelly G. Adel, PharmD, BCOP, BCPS, Juliet N Barker, MBBS, (Hons), FRACP

Blood (2013) 122 (21): 3297.

https://doi.org/10.1182/blood.V122.21.3297.3297

Published: 2013

Journal Articles

Cytidine Deaminase Status As a Predictive Marker Of Response and Toxicity In Patients With Haematological Malignancies Treated With Azacytidine Or Cytarabine

Cédric Mercier, MD, Raphaelle Fanciullino, PhD, Cindy Serdjebi, Joseph Ciccolini, PhD, Bertrand Pourroy, Gerard Milano, L’Houcine Ouafik, MD, PhD, Régis T Costello, Sr., MD, PhD

Blood (2013) 122 (21): 3862.

https://doi.org/10.1182/blood.V122.21.3862.3862

Published: 2013

Journal Articles

Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease

Suzette O. Oyeku, MD, MPH, Nancy S. Green, MD, Farzana Pashankar, MD, Patricia Giardina, MD, Craig A. Mullen, MD, PhD, Catherine Driscoll, MD

Blood (2010) 116 (21): 255.

https://doi.org/10.1182/blood.V116.21.255.255

Published: 2010

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Ricardo Pasquini, MD, Jorge Cortes-Franco, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Zhixiang Shen, MD, PhD, Luis Meillon, MD, Lidia Mongay, MD, PhD, MBA, Dawn F. Eng, Jim Wang, PhD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD

Blood (2009) 114 (22): 4267.

https://doi.org/10.1182/blood.V114.22.4267.4267

Published: 2009

Journal Articles

Adherence with Hydroxyurea in Children with Sickle Cell Disease

Courtney D. Thornburg, MD, MS, Agustin Calatroni, MS, Brittany Herzberg, Marilyn J. Telen, MD, Alex Kemper, MD, MPH, MS

Blood (2008) 112 (11): 167.

https://doi.org/10.1182/blood.V112.11.167.167

Published: 2008

Journal Articles

Micafungin Does Not Influence the Concentration of Tacrolimus in Patients after Allogeneic Hematopoietic Stem Cell Transplantation.

Noriyasu Fukuoka, Osamu Imataki, Hiroaki Ohnishi, Akira Kitanaka, Yoshitsugu Kubota, Terukazu Tanaka, Toshihiko Ishida

Blood (2007) 110 (11): 4938.

https://doi.org/10.1182/blood.V110.11.4938.4938

Published: 2007

Journal Articles

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Carolyn Blasdel, MA, RN, FNP, Yanfeng Wang, PhD, Theodore Lagattuta, BS, Brian Druker, MD, Laurie Letvak, MD, Merrill Egorin, MD FACP

Blood (2006) 108 (11): 4820.

https://doi.org/10.1182/blood.V108.11.4820.4820

Published: 2006

Journal Articles

A Population Pharmacokinetic Model Describing the Activity-Time-Course of PEG-Asparaginase in Children.

Georg Hempel, Claudia Lanvers-Kaminsky, Hans-Joachim Mueller, Gudrun Wuerthwein, Joachim Boos

Blood (2004) 104 (11): 2746.

https://doi.org/10.1182/blood.V104.11.2746.2746

Published: 2004

NARROW

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Drug Monitoring of Asparaginase Activity to Detect Silent Inactivation in Pediatric Acute Lymphoblastic Leukemia Patients Receiving Peg-Asparaginase

Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns

Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Evaluating Frequency of Anti-Xa Monitoring in Treatment of Pediatric Venous Thromboembolism

Efficacy and Safety of Rivaroxaban: An Observationalmulticenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

Intensified Mycophenolate Mofetil (MMF) Dosing Every 8 Hours Is Safe From The Standpoint Of Engraftment and May Ameliorate Severe Acute Graft-Versus-Host Disease (GVHD) After Double-Unit Cord Blood Transplantation (CBT)

Should We Use a Desensitization Protocol In Acute Lymphoblastic Leukemia Patients With Silent Inactivation Of Pegasparaginase?

A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia

Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients

Cytidine Deaminase Status As a Predictive Marker Of Response and Toxicity In Patients With Haematological Malignancies Treated With Azacytidine Or Cytarabine

Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Adherence with Hydroxyurea in Children with Sickle Cell Disease

Micafungin Does Not Influence the Concentration of Tacrolimus in Patients after Allogeneic Hematopoietic Stem Cell Transplantation.

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

A Population Pharmacokinetic Model Describing the Activity-Time-Course of PEG-Asparaginase in Children.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only